Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $53.14M rose 20.7% year over year, ahead of the +13.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.

Context

  • Selling, general & admin amounted to 62.5% of revenue in FY2025, down 18.0 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $490.31M (+168.8%) for the fiscal year ending Dec 2026, a step up from the +11.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.14M+11.9% QoQ
Last fiscal yearDec 2025
$182.37M+11.6% YoY
LTMMar 2026
$191.5M+13.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.7%+147.9%+127.2 pp
1 year+11.6%+168.8%+157.3 pp
3-year CAGR+9.8%+62.5%+52.7 pp
5-year CAGR+43.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
182.37M USD
Year-over-year change
+11.6%
4-year CAGR
+9.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.2% is the lowest of 9, against a peer median of +45.6%.
  • Selling, general & admin amounts to 60.8% of revenue for XERS, versus a peer median of 48.0%.
XERS Competitors
Selling, General & Admin for XERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€598.18M EUR+52.7%+26.4%49.5%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$556.47M USD+58.3%+43.2%67.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$191.5M USD+13.2%+9.8%60.8%
MNKDMannKind CorporationLTM Mar 2026$173.21M USD+78.5%+16.4%48.0%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$59.07M USD+263.5%+71.2%—
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$37.1M USD+38.6%+24.5%42.7%
SEPNSepterna, Inc.LTM Sep 2026$36.57M USD+38.0%—38.0%
GHRSGH Research PLCLTM Mar 2026$23.07M USD+35.6%+29.0%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$17.75M USD+26.9%+12.0%—
Peer median (excluding XERS) —+45.6%+26.4%48.0%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.